drugset / Trial / NCT00366704
Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint
Phase 3
Terminated
400 enrolled
Wyeth is now a wholly owned subsidiary of Pfizer
Solvay Pharmaceuticals · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the effect of bifeprunox or risperidone on the body weight of patients with schizophrenia.
Timeline
- Start
- 2006-11
- Primary completion
- 2008-03
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bifeprunox | Small molecule | 30 mg | — |
| Comparator | Risperidone | Other / unclassified | 4 mg | — |